Aardvark Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $108.5M
- Price
- $4.96
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.59%
- Volume
- 212.1K
About
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Quick stats
Shares outstanding21.9M
Computed float12.1M
Float / shares55.5%
Cash runway (months)9.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001774857
AI Summary
AI-generated1/50
minorneutrallegal litigation
Aardvark Therapeutics (AARD) Investors: Securities Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Hagens Berman issued a solicitation notice for a pending securities class action against Aardvark Therapeutics, with a lead plaintiff deadline of October 13, 2026.
The suit covers IPO purchasers and investors between February 13, 2025 and May 14, 2026, alleging ARD-101's safety risks, including QRS prolongation, were concealed; the stock fell 56% after the Phase 3 HERO trial pause and 32.1% more after the FDA's full clinical hold.
This is law-firm marketing rather than a new issuer disclosure; the underlying clinical events were previously announced.
Red flags
- ongoing securities class action alleging ARD-101 safety misstatements
- FDA full clinical hold on ARD-101 IND halting Phase 3 HERO and OLE trials